David C. Limburg

机构：Pfizer (United States)

发表论文 37 篇 · 总被引 1175 次 · h-index 15

代表论文

• The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life (2010 · Bioorganic & Medicinal Chemistry Letters · 被引 341)
• Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841) (2018 · Journal of Medicinal Chemistry · 被引 176)
• Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay (2012 · Journal of Medicinal Chemistry · 被引 79)
• Selective inducible microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from an oxicam template (2010 · Bioorganic & Medicinal Chemistry Letters · 被引 61)
• Automated Nanomole-Scale Reaction Screening toward Benzoate Bioisosteres: A Photocatalyzed Approach to Highly Elaborated Bicyclo[1.1.1]Pentanes (2021 · ACS Catalysis · 被引 49)
• The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates (2010 · Bioorganic & Medicinal Chemistry Letters · 被引 37)